monrd0024
Medals oligonucleic drug ID monrd0024
ATC Classification S01LA03
Product Name Macugen
Synonims Pegaptanib
Country Germany
US
Company Society (Institute) for clinical research
(OSI) Eyetech, Inc
phase AD
Type Aptamer
Adaptation Diseases Wet Macular Degeneration
neovascular age-related macular degeneration
Target Molecule VEGF
Remarks Macugen is used for the treatment of angiogenic age-related macular degeneration (AMD).
Nucleic Acid Sequence ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT), 5'-ester with α,α'-[4,12-dioxo-6[[[5-(phosphoonoxy)pentyl]amino] carbonyl]-3,13-dioxa-5,11-diaza-1,15pentadecanediyl]bis[ω-methoxypoly(oxy-1,2-ethanediyl)]
Source http://www.rxlist.com/macugen-drug.htm,
http://www.kegg.jp/dbget-bin/www_bget?D05386,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006290-90/DE,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000722-31/DE
DrugBank DB04895
TargetProtein - UniProt P15692
TargetProtein - PDB 3BDY